Begelomab

• CAT Number: I042160
• CAS Number: 1403744-56-8
• Purity: ≥95%

Begelomab（Cat No.:I042160）is an investigational monoclonal antibody that targets the immune checkpoint receptor LAG-3 (lymphocyte-activation gene 3), which plays a role in suppressing immune responses, particularly in the tumor microenvironment. LAG-3 expression on immune cells, such as T-cells, inhibits their activity, allowing tumors to evade immune detection. By blocking LAG-3, begelomab aims to enhance the immune system’s ability to recognize and attack cancer cells. It is being studied in clinical trials for its potential to treat various cancers, including solid tumors, with the goal of improving patient outcomes by restoring immune function.